Last reviewed · How we verify
Vaginal and blood sample collection
At a glance
| Generic name | Vaginal and blood sample collection |
|---|---|
| Sponsor | Unity Health Toronto |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer (PHASE3)
- Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma (PHASE3)
- Testing RG1-VLP Vaccine to Prevent HPV-related Cancers (PHASE1)
- Impact of Internal Menstrual Protections on Immunity and Vaginal Microbiota
- Impact of Surgery for Deep Posterior Endometriosis on Ovarian Reserve (ENDORO) (NA)
- Long-Term Follow-Up in Women With Early Breast Cancer Three Years of More Post Primary Treatment
- Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant Recipients (PHASE2)
- "Pregnancy and Viral Infections: Impact on Pregnant Women and Their Children. French Prospective Cohort"
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vaginal and blood sample collection CI brief — competitive landscape report
- Vaginal and blood sample collection updates RSS · CI watch RSS
- Unity Health Toronto portfolio CI